United Therapeutics (UTHR) Long-Term Investments (2009 - 2026)

United Therapeutics has disclosed Long-Term Investments across 18 years of filings, most recently posting $1.1 billion for Q2 2026.

• In Q2 2026, Long-Term Investments fell 40.5% year-over-year to $1.1 billion; the TTM figure through Jun 2026 stood at $1.1 billion (down 40.5% YoY), while the FY2025 annual figure was $1.8 billion, up 20.43% from the prior year.
• Long-Term Investments came in at $1.1 billion for Q2 2026 at United Therapeutics, down from $1.3 billion in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $2.1 billion in Q3 2023 to a low of $1.1 billion in Q2 2026.
• Average Long-Term Investments over 5 years is $1.6 billion, with a median of $1.6 billion recorded in 2022.
• Year-over-year, Long-Term Investments jumped 45.1% in 2023 and tumbled 40.5% in 2026.
• Over 5 years, Long-Term Investments stood at $1.3 billion in 2022, then jumped by 45.1% to $1.9 billion in 2023, then dropped by 22.75% to $1.5 billion in 2024, then increased by 20.43% to $1.8 billion in 2025, then plunged by 35.77% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $1.1 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.8 billion in Q4 2025.